Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13678588 | 1.00 | MAPK14 (0.47) | MAPK14MAPK12MAPK11MAPK13JAK3 | |
| SCHEMBL4521316 | 1.00 | MAPK14 (0.47) | MAPK14MAPK12MAPK11MAPK13JAK3 | |
| SCHEMBL13678589 | 0.95 | MAPK14 (0.45) | MAPK14MAPK12MAPK11MAPK13JAK3 | |
| SCHEMBL4512413 | 0.95 | MAPK14 (0.45) | MAPK14MAPK12MAPK11MAPK13JAK3 | |
| SCHEMBL4512411 | 0.95 | MAPK14 (0.45) | MAPK14MAPK12MAPK11MAPK13JAK3 | |
| SCHEMBL4500788 | 0.92 | MAPK14 (0.48) | MAPK14MAPK12MAPK11MAPK13CDK8 | |
| SCHEMBL4509870 | 0.91 | MAPK14 (0.50) | MAPK14MAPK12MAPK11MAPK13CDK8 | |
| SCHEMBL4500943 | 0.90 | MAPK14 (0.51) | MAPK14MAPK12MAPK11MAPK13CDK8 | |
| SCHEMBL4502295 | 0.89 | MAPK14 (0.48) | MAPK14MAPK12MAPK11MAPK13PTK2B | |
| SCHEMBL4505139 | 0.89 | MAPK14 (0.51) | MAPK14MAPK12MAPK11MAPK13CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| EP-1987022-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | Pfizer Products Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PDXK, UMPS, CDK2 | MAPK14 117/4885MAPK12 178/4885MAPK11 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.